Product Information
PENTASA 250 MG CAPSULE is a brand product labeled by Takeda Pharmaceuticals America, Inc., priced at $2.9009 per EA under NDC 54092018981. Its NADAC has been published 658 times since Nov 28, 2013.
FDA first approved this application on May 10, 1993. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the mesalamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
250 mg/1
Manufacturer
Takeda Pharmaceuticals America, Inc.NDC
54092018981
Classification
Brand
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
New Drug (NDA)
FDA Application
NDA020049FDA Approved
5/10/1993
TE Code
AB
On Market Since
5/10/1993
Pharmacological Classes
Price Statistics
The NADAC for PENTASA 250 MG CAPSULE has been published 658 times since Nov 28, 2013, and over the history we have for it it has risen 76.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.9009 per EA |
|---|---|
| All-time high | $2.9261 (Aug 14, 2019) |
| All-time low | $1.6478 (Nov 28, 2013) |
| 52-week high | $2.9126 |
| 52-week low | $2.9009 |
| Median price | $2.9056 |
| Average price | $2.6718 |
| Largest weekly change | +9.0% (Apr 8, 2015) |
| Weeks tracked | 658 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the mesalamine market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Takeda Pharmaceuticals America, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PENTASA 250 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for PENTASA 250 MG CAPSULE, manufactured by Takeda Pharmaceuticals America, Inc., is $2.9009 per EA (NDC 54092018981), effective Sep 30, 2026.
How has the price of PENTASA 250 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for PENTASA 250 MG CAPSULE has risen 76.0%. It has been tracked across 658 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for PENTASA 250 MG CAPSULE?
Since Nov 28, 2013, the NADAC for PENTASA 250 MG CAPSULE has ranged from a low of $1.6478 (Nov 28, 2013) to a high of $2.9261 (Aug 14, 2019), with a median of $2.9056 per EA.
Are there cheaper alternatives to PENTASA 250 MG CAPSULE?
No other NADAC-published product currently shares the active ingredient and strength of PENTASA 250 MG CAPSULE in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PENTASA 250 MG CAPSULE?
PENTASA 250 MG CAPSULE (NDC 54092018981) is labeled by Takeda Pharmaceuticals America, Inc., and CMS classifies it as a brand product.